Clinical Trials
11 trialsNCT02465060 2026-06-03
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT01441089 2026-04-14
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
National Institutes of Health Clinical Center (CC)
Recruiting
NCT00001503 2023-06-18
Follow-up Protocol for Patients With Cancer/AIDS/Skin Disease
National Institutes of Health Clinical Center (CC)
Completed
NCT00036712 2013-09-20
Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00005590 2013-08-02
Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma
National Cancer Institute (NCI)
Phase 3 Completed
NCT00003408 2013-03-26
Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00019019 2012-03-15
Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00030108 2012-03-15
Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven't Responded to Therapy
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00064311 2012-03-08
Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT00001302 2008-03-04
A Phase I Study of Infusional Chemotherapy With the P-Glycoprotein Antagonist PSC 833
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00001383 2008-03-04
A Phase I Study of Infusional Paclitaxel With the P-Glycoprotein Antagonist PSC 833
National Institutes of Health Clinical Center (CC)
Phase 1 Completed